Author’s response to reviews

Title: The Procalcitonin And Survival Study (PASS) - A Randomised multi-center trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients

Authors:

Jens-Ulrik Jensen (koordinator@pass-studiet.dk)
Bettina E Lundgren (bettina.lundgren@hvh.regionh.dk)
Lars Hein (larshein@post5.tele.dk)
Thomas Mohr (t.mohr@dadlnet.dk)
Pernille L Petersen (pernille.lykke.petersen@dadlnet.dk)
Lasse H Andersen (lasse.andersen@dadlnet.dk)
Anne Ø Lauritsen (annelauritsen@dadlnet.dk)
Sine Hougaard (thomassine@hotmail.com)
Teit Mantoni (temantoni@hotmail.com)
Bonnie Bømler (bon_bom@hotmail.com)
Klaus J Thornberg (klaust@dadlnet.dk)
Katrin Thormar (kata@tdcadsl.dk)
Jesper Løkken (jesper.loeken@hvh.regionh.dk)
Morten Steensen (morten.steensen@hvh.regionh.dk)
Peder Carl (peder.carl@hvh.regionh.dk)
J. Asger Petersen (john.asger.petersen@hvh.regionh.dk)
Hamid Tousi (hamid.tousi@yahoo.com)
Peter Søe-Jensen (pesj@heh.regionh.dk)
Morten MB Bestle (mbes@hih.regionh.dk)
Søren Hestad (s.hestad@dadlnet.dk)
Mads H Andersen (mha@dadlnet.dk)
Paul Fjeldborg (pfb@sks.aaa.dk)
Kim M Larsen (kml@dadlnet.dk)
Charlotte D CDR Rossau (cdr@dadlnet.dk)
Carsten B Thomsen (cbth@mail.dk)
Christian Østergaard (coa@ssi.dk)
Jesper K Kjær (jkk@cphiv.dk)
Jesper Grarup (jgr@cphiv.dk)
Jens D Lundgren (jdl@cphiv.dk)

Version: 2 Date: 26 June 2008

Author’s response to reviews:

Dear Editor,

On invitation from the editor at BMC Health Services Research, we hereby transfer our study protocol manuscript to BMC Infectious Diseases. Two changes
have been made. The abstract has been restructured and one author has corrected his affiliations.

Below, I have pasted the original cover letter regarding our ongoing study:

Apart from this, we refer kindly to our previous cover letter, outlining some of the main reasons for conducting a large scale mortality endpoint randomized controlled trial with procalcitonin-guided treatment in critically ill patients.

Best regards,

Jens-Ulrik Jensen, MD, Project Coordinator, The Procalcitonin And Survival Study (PASS)